Related Experiment Video
Updated: Jun 13, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Docetaxel-Induced Cell Death Is Regulated by a Fatty Acid-Binding Protein 12-Slug-Survivin Pathway in Prostate Cancer
Rong-Zong Liu1, Mansi Garg1, Xiao-Hong Yang1
1Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Abstract:
Chemotherapy is an important treatment option for advanced prostate cancer, especially for metastatic prostate cancer (PCa). Resistance to first-line chemotherapeutic drugs such as docetaxel often accompanies prostate cancer progression. Attempts to overcome resistance to docetaxel by combining docetaxel with other biological agents have been mostly unsuccessful. A better understanding of the mechanisms underlying docetaxel resistance may provide new avenues for the treatment of advanced PCa. We have previously found that the fatty acid-binding protein 12 (FABP12)-PPARγ pathway modulates lipid-related bioenergetics and PCa metastatic transformation through induction of Slug, a master driver of epithelial-to-mesenchymal transition (EMT). Here, we report that the FABP12-Slug axis also underlies chemoresistance in PCa cells. Cell sensitivity to docetaxel is markedly suppressed in FABP12-expressing cells, along with induction of Survivin, a typical apoptosis inhibitor, and inhibition of cleaved PARP, a hallmark of programmed cell death. Importantly, Slug depletion down-regulates Survivin and restores cell sensitivity to docetaxel in FABP12-expressing cells. Finally, we also show that high levels of Survivin are associated with poor prognosis in PCa patients, with FABP12 status determining its prognostic significance. Our research identifies a FABP12-Slug-Survivin pathway driving docetaxel resistance in PCa cells, suggesting that targeting FABP12 may be a precision approach to improve chemodrug efficacy and curb metastatic progression in PCa.
Insights
A newly identified pathway involving fatty acid-binding protein 12 (FABP12) and Slug drives docetaxel resistance in prostate cancer (PCa). Targeting FABP12 may improve chemotherapy effectiveness and reduce metastatic spread in PCa patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Docetaxel resistance is a major challenge in advanced prostate cancer (PCa) treatment.
- Previous research linked fatty acid-binding protein 12 (FABP12) to PCa metastasis via the PPARγ-Slug pathway.
- Understanding chemoresistance mechanisms is crucial for developing new therapeutic strategies.
Purpose of the Study:
- To investigate the role of the FABP12-Slug axis in docetaxel resistance in prostate cancer cells.
- To identify molecular mechanisms underlying chemoresistance in FABP12-expressing PCa cells.
- To evaluate the prognostic significance of the FABP12-Slug-Survivin pathway in PCa patients.
Main Methods:
- Investigated docetaxel sensitivity in FABP12-expressing PCa cells.
- Assessed levels of apoptosis markers (Survivin, cleaved PARP) in relation to FABP12 and Slug expression.
- Performed Slug depletion experiments to observe effects on docetaxel sensitivity and Survivin levels.
- Correlated Survivin levels and FABP12 status with patient prognosis.
Main Results:
- FABP12 expression suppressed docetaxel sensitivity in PCa cells, accompanied by increased Survivin and decreased cleaved PARP.
- Slug depletion reversed docetaxel resistance and reduced Survivin levels in FABP12-expressing cells.
- High Survivin levels correlated with poor PCa prognosis, with FABP12 status influencing this association.
Conclusions:
- A FABP12-Slug-Survivin pathway contributes to docetaxel resistance in prostate cancer.
- Targeting FABP12 presents a potential precision medicine approach to enhance chemotherapy efficacy.
- This pathway may also play a role in curbing metastatic progression in prostate cancer.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Abnormal Proliferation
Regulation of the Unfolded Protein Response
Drugs that Stabilize Microtubules

